Cargando…
EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50%
Targeted therapies are on the market for the past five years and recently pembrolizumab was approved as first line treatment for patients with PD-L1 >50%. We present three cases of patients which had epidermal growth factor receptor positive expression and programmed death-ligand 1 (PD-L1), PD-L1...
| Autores principales: | , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524632/ https://www.ncbi.nlm.nih.gov/pubmed/28761805 http://dx.doi.org/10.1016/j.rmcr.2017.05.010 |
| _version_ | 1783252485264113664 |
|---|---|
| author | Zarogoulidis, Paul Chinelis, Panos Efthymiou, Christofors Athanasiadou, Anastasia Mpikos, Vasilis Papatsibas, George Papadopoulos, Vasilis Maragouli, Elena Huang, Haidong Trakada, Georgia Kallianos, Anastasios Veletza, Lemonia Hohenforst-Schmidt, Wolfgang |
| author_facet | Zarogoulidis, Paul Chinelis, Panos Efthymiou, Christofors Athanasiadou, Anastasia Mpikos, Vasilis Papatsibas, George Papadopoulos, Vasilis Maragouli, Elena Huang, Haidong Trakada, Georgia Kallianos, Anastasios Veletza, Lemonia Hohenforst-Schmidt, Wolfgang |
| author_sort | Zarogoulidis, Paul |
| collection | PubMed |
| description | Targeted therapies are on the market for the past five years and recently pembrolizumab was approved as first line treatment for patients with PD-L1 >50%. We present three cases of patients which had epidermal growth factor receptor positive expression and programmed death-ligand 1 (PD-L1), PD-L1 >50% overexpression. |
| format | Online Article Text |
| id | pubmed-5524632 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-55246322017-07-31 EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50% Zarogoulidis, Paul Chinelis, Panos Efthymiou, Christofors Athanasiadou, Anastasia Mpikos, Vasilis Papatsibas, George Papadopoulos, Vasilis Maragouli, Elena Huang, Haidong Trakada, Georgia Kallianos, Anastasios Veletza, Lemonia Hohenforst-Schmidt, Wolfgang Respir Med Case Rep Case Report Targeted therapies are on the market for the past five years and recently pembrolizumab was approved as first line treatment for patients with PD-L1 >50%. We present three cases of patients which had epidermal growth factor receptor positive expression and programmed death-ligand 1 (PD-L1), PD-L1 >50% overexpression. Elsevier 2017-05-30 /pmc/articles/PMC5524632/ /pubmed/28761805 http://dx.doi.org/10.1016/j.rmcr.2017.05.010 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Case Report Zarogoulidis, Paul Chinelis, Panos Efthymiou, Christofors Athanasiadou, Anastasia Mpikos, Vasilis Papatsibas, George Papadopoulos, Vasilis Maragouli, Elena Huang, Haidong Trakada, Georgia Kallianos, Anastasios Veletza, Lemonia Hohenforst-Schmidt, Wolfgang EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50% |
| title | EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50% |
| title_full | EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50% |
| title_fullStr | EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50% |
| title_full_unstemmed | EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50% |
| title_short | EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50% |
| title_sort | egfr or pd-l1 decision for first line therapy in a case series of egfr positive and pd-l1 >50% |
| topic | Case Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524632/ https://www.ncbi.nlm.nih.gov/pubmed/28761805 http://dx.doi.org/10.1016/j.rmcr.2017.05.010 |
| work_keys_str_mv | AT zarogoulidispaul egfrorpdl1decisionforfirstlinetherapyinacaseseriesofegfrpositiveandpdl150 AT chinelispanos egfrorpdl1decisionforfirstlinetherapyinacaseseriesofegfrpositiveandpdl150 AT efthymiouchristofors egfrorpdl1decisionforfirstlinetherapyinacaseseriesofegfrpositiveandpdl150 AT athanasiadouanastasia egfrorpdl1decisionforfirstlinetherapyinacaseseriesofegfrpositiveandpdl150 AT mpikosvasilis egfrorpdl1decisionforfirstlinetherapyinacaseseriesofegfrpositiveandpdl150 AT papatsibasgeorge egfrorpdl1decisionforfirstlinetherapyinacaseseriesofegfrpositiveandpdl150 AT papadopoulosvasilis egfrorpdl1decisionforfirstlinetherapyinacaseseriesofegfrpositiveandpdl150 AT maragoulielena egfrorpdl1decisionforfirstlinetherapyinacaseseriesofegfrpositiveandpdl150 AT huanghaidong egfrorpdl1decisionforfirstlinetherapyinacaseseriesofegfrpositiveandpdl150 AT trakadageorgia egfrorpdl1decisionforfirstlinetherapyinacaseseriesofegfrpositiveandpdl150 AT kallianosanastasios egfrorpdl1decisionforfirstlinetherapyinacaseseriesofegfrpositiveandpdl150 AT veletzalemonia egfrorpdl1decisionforfirstlinetherapyinacaseseriesofegfrpositiveandpdl150 AT hohenforstschmidtwolfgang egfrorpdl1decisionforfirstlinetherapyinacaseseriesofegfrpositiveandpdl150 |